Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.66 |
| ▸ | PDE2A | O00408 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.66 |
| ▸ | PDE6D | O43924 | 1/20 | 0.66 |
| ▸ | PDE8A | O60658 | 1/20 | 0.66 |
| ▸ | PDE9A | O76083 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | PDE6A | P16499 | 1/20 | 0.66 |
| ▸ | PDE6G | P18545 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | PDE6B | P35913 | 1/20 | 0.66 |
| ▸ | PDE6C | P51160 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450733 | 1.00 | PDE5A (0.66) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5452865 | 0.95 | PDE5A (0.62) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5452873 | 0.95 | PDE5A (0.62) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5467118 | 0.93 | PDE5A (0.56) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5467113 | 0.93 | PDE5A (0.56) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5455423 | 0.92 | PDE5A (0.57) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5455416 | 0.92 | PDE5A (0.57) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL6497382 | 0.92 | PDE5A (0.79) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL29394704 | 0.92 | PDE5A (0.79) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL30434848 | 0.92 | PDE5A (0.79) | PDE5APDE3BPDE3APDE2AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | THE INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2007-09-20 | — | — | US | claimed |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210100807-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2021-04-08 | — | — | US | disclosed |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2021-02-18 | — | — | US | disclosed |
| US-20160256381-A9 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160067252-A1 | TRANSDERMAL DELIVERY OF SILDENAFIL AND OTHER PHOSPHODIESTERASE TYPE 5 INHIBITORS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067252-A1 | TRANSDERMAL DELIVERY OF SILDENAFIL AND OTHER PHOSPHODIESTERASE TYPE 5 INHIBITORS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20140086980-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140086980-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140051707-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051707-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | THE INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1695976-A1 | PYRAZOLOPYRIMIDINETHIONE DERIVATIVES, SALTS AND SOLVATES THEREOF, PREPARATION METHODS AND USE THEREOF | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20140086980-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE3B 2/4885PDE3A 3/4885 |
| US-20160067252-A1 | TRANSDERMAL DELIVERY OF SILDENAFIL AND OTHER PHOSPHODIESTERASE TYPE 5 INHIBITORS | PDE5A, PDE12, PDE2A | PDE5A 1/4885PDE3B 5/4885PDE3A 4/4885 |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | LIPA, MMP8, MMP1 | PDE5A 1804/4885PDE3B 1115/4885PDE3A 988/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | PDE5A 2948/4885PDE3B 1823/4885PDE3A 1803/4885 |
| US-20140051707-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20160256381-A9 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | FABP7, LIPA, LIPC | PDE5A 2202/4885PDE3B 1581/4885PDE3A 1141/4885 |
| US-20210100807-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | MGLL, LIPA, LAMP1 | PDE5A 2553/4885PDE3B 1872/4885PDE3A 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.